← Back to Clinical Trials
Recruiting NCT06423430

Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)

Trial Parameters

Condition Treatment Resistant Depression
Sponsor Abbott Medical Devices
Study Type INTERVENTIONAL
Phase N/A
Enrollment 100
Sex ALL
Min Age 22 Years
Max Age 70 Years
Start Date 2024-09-11
Completion 2027-04
Interventions
Sham-stimulationActive-stimulation

Brief Summary

The goal of this clinical trial is to evaluate the effectiveness and safety of bilateral stimulation of the subcallosal cingulate white matter (SCCwm) using Deep Brain Stimulation (DBS) as an adjunctive treatment of non-psychotic unipolar Major Depressive Disorder (MDD) in adults.

Eligibility Criteria

Inclusion Criteria: 1. The patient must be diagnosed with non-psychotic unipolar Major Depressive Disorder. 2. The patient must be in a major depressive episode for ≥12 months or have had at least 3 lifetime depressive episodes. 3. The patient has tried and failed a minimum of four different types of antidepressant treatments as measured by a tool designed for this purpose. 4. Depression medication and treatment regimen must be stable for a minimum of 4 weeks before the first baseline visit Exclusion Criteria: 1. Pregnant or those who plan to become pregnant during study 2. Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that could limit participation in the study or interfere with adherence to the study protocol. 3. Current or lifetime history of psychotic features in any Major Depressive Episode. 4. Has an intracranial Central Nervous System disease that impairs motor, sensory or cognitive function or that requires intermittent

Related Trials